# Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis

> **NCT01022060** · PHASE3 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 110 (actual)

## Conditions studied

- Recurrent Calcic Urolithiasis

## Interventions

- **DIETARY_SUPPLEMENT:** Renalof
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT01022060
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2010-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022060, "Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01022060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*